Read The Official Patient's Sourcebook on Lupus Online
Authors: MD James N. Parker,PH.D Philip M. Parker
Association; produced by Dave Bell Associates; Year: 1974; Format:
Videorecording; Garden Grove, Ca.: Trainex, 1974
·
Lupus erythematosus, collagen-vascular diseases, and eczema.
Source: Dept. of Medicine, Emory University, School of Medicine; Year: 1979;
Format: Videorecording; Atlanta: Emory Medical Television Network:
[for loan and sale by A. W. Calhoun Medical Library, 1979]
·
Lupus-- insights, emotions, encouragements.
Source: written and
produced by William & Estelle Gill, in cooperation with the Lupus
Foundation of America, Inc., Marcy Zitron Chapter, Columbus, Ohio;
Year: 1993; Format: Videorecording; Columbus, Ohio: Production House;
Media, PA: Media Inc., c1993
·
Nephrology.
Source: American Medical Association; Year: 1997; Format: Electronic resource; Newton, MA: SilverPlatter Education, 1997
·
Nephrotic syndrome in chronic nephritis.
Source: Department of Medicine, Emory University, School of Medicine; Year: 1980; Format:
Videorecording; Atlanta: Emory Medical Television Network: [for loan or
sale by A. W. Calhoun Medical Library], 1980
Multimedia 87
·
Nephrotic syndrome.
Source: E. Lovell Becker, Jacob Churg; Year: 1972; Format: Slide; New York: Medcom, c1972
·
Renal biopsy.
Source: Richard R. Lindquist; Year: 1970; Format: Slide;
[New York]: Medcom, c1970
·
Steroids and immunosuppressive drugs in renal disease.
Source: Video Digest, inc; Year: 1972; Format: Motion picture; Cincinnati, Ohio: Video
Digest, c1972
·
Systemic lupus erythematosis.
Source: presented by the Department of Pediatrics, Emory University, School of Medicine; Year: 1984; Format:
Videorecording; Atlanta, Ga.: Emory Medical Television Network, 1984
·
Systemic lupus erythematosus (SLE) : it means some changes.
Source: Biomedical Media Production Unit, the University of Michigan Medical
Center, Office of Educational Resources & Research; Year: 1981; Format:
Videorecording; Ann Arbor, Mich.: University of Michigan, c1981
·
Systemic lupus erythematosus.
Source: Ellen M. Ginzler; Year: 1979; Format: Slide; [New York]: Medcom, c1979
·
Systemic lupus.
Source: produced by Audio Master; Year: 1988; Format: Sound recording; [Atlanta, Ga.]: American Rheumatism Association,
[1988]
·
Treatment of lupus.
Source: presented by the Department of Medicine, Emory University, School of Medicine; Year: 1985; Format:
Videorecording; Atlanta, Ga.: Emory Medical Television Network, 1985
·
Tubulo-interstitial disease.
Source: Harry G. Preuss, George E.
Schreiner; Year: 9999; Format: Slide; [New York]: Medcom, c1980-
·
Voices of lupus.
Source: [presented by] Films for the Humanities & Sciences, the Wolf Pack and the Hospital for Special Surgery; a Harriet
Fier & Stephen Mantell Production; Year: 1992; Format: Videorecording;
Princeton, N.J.: Films for the Humanities & Sciences, c1992
Vocabulary Builder
Dermatology:
A medical specialty concerned with the skin, its structure, functions, diseases, and treatment. [NIH]
Eczema:
A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents, characterized in the acute stage by
erythema, edema associated with a serous exudate between the cells of the
epidermis (spongiosis) and an inflammatory infiltrate in the dermis, oozing
and vesiculation, and crusting and scaling; and in the more chronic stages by
lichenification or thickening or both, signs of excoriations, and
88 Lupus Nephritis
hyperpigmentation or hypopigmentation or both. Atopic dermatitis is the
most common type of dermatitis. Called also eczematous dermatitis. [EU]
Edema:
Excessive amount of watery fluid accumulated in the intercellular spaces, most commonly present in subcutaneous tissue. [NIH]
Empyema:
Accumulation of pus in a cavity of the body; when used without a descriptive qualifier, it refers to thoracic empyema (q.v.). [EU]
Fistula:
An abnormal passage or communication, usually between two
internal organs, or leading from an internal organ to the surface of the body; frequently designated according to the organs or parts with which it
communicates, as anovaginal, brochocutaneous, hepatopleural,
pulmonoperitoneal, rectovaginal, urethrovaginal, and the like. Such passages
are frequently created experimentally for the purpose of obtaining body
secretions for physiologic study. [EU]
Periodicals and News 89
CHAPTER 8. PERIODICALS AND NEWS ON LUPUS
NEPHRITIS
Overview
Keeping up on the news relating to lupus nephritis can be challenging.
Subscribing to targeted periodicals can be an effective way to stay abreast of recent developments on lupus nephritis. Periodicals include newsletters,
magazines, and academic journals.
In this chapter, we suggest a number of news sources and present various
periodicals that cover lupus nephritis beyond and including those which are
published by patient associations mentioned earlier. We will first focus on
news services, and then on periodicals. News services, press releases, and
newsletters generally use more accessible language, so if you do chose to
subscribe to one of the more technical periodicals, make sure that it uses
language you can easily follow.
News Services & Press Releases
Well before articles show up in newsletters or the popular press, they may
appear in the form of a press release or a public relations announcement.
One of the simplest ways of tracking press releases on lupus nephritis is to
search the news wires. News wires are used by professional journalists, and
have existed since the invention of the telegraph. Today, there are several
major “wires” that are used by companies, universities, and other
organizations to announce new medical breakthroughs. In the following
sample of sources, we will briefly describe how to access each service. These
services only post recent news intended for public viewing.
90 Lupus Nephritis
PR Newswire
Perhaps the broadest of the wires is PR Newswire Association, Inc. To access
this archive, simply go to
http://www.prnewswire.com
. Below the search
box, select the option “The last 30 days.” In the search box, type “lupus
nephritis” or synonyms. The search results are shown by order of relevance.
When reading these press releases, do not forget that the sponsor of the
release may be a company or organization that is trying to sell a particular
product or therapy. Their views, therefore, may be biased.
·
Lupus, Psoriasis and Arthritis Foundation Leaders and Biotechnology
Industry Discuss Ways to Increase Clinical Trial Enrollment at BIO
2002
Summary: San Diego, June 11 /PRNewswire-FirstCall/ -- La Jolla
Pharmaceutical Company (Nasdaq: LJPC) today announced that industry
and leaders of the national lupus, arthritis and psoriasis patient advocacy
organizations will discuss clinical trial enrollment at the Biotechnology
Industry Organization (BIO) 2002 International Conference and
Exhibition in Toronto, Canada this morning at 8:30 a.m.
"The good news is that the biotechnology industry is developing an
unprecedented wave of drug candidates, offering hope of potential new
therapies. Unfortunately, a lack of patients to participate in this growing
number of clinical trials will pose a significant bottleneck to the
availability of these promising drugs," said Steven B. Engle, La Jolla
Pharmaceutical Company's Chairman and CEO. "By working together,
patient advocacy groups, biotechnology companies and others can
educate the public on the critical importance of clinical trial
participation."
"Voluntary health associations bring together patients and companies
seeking to develop new therapies for a range of diseases," said Gail M.
Zimmerman, President and CEO of the National Psoriasis Foundation.
"Through awareness, education and ensuring access to clinical trials, we
can help in the race to provide new treatments to patients who may
otherwise be faced with limited options for care."
The panel will include Ms. Zimmerman; Sandra Claire Raymond,
President and CEO of the Lupus Foundation of America; and Tino J.
Mantella, President and CEO of the Arthritis Foundation. Mr. Engle will
chair the panel. The panel discussion is entitled "Changing the Future of Clinical Trial Recruitment by Building Ties with Patient Advocates."
Periodicals and News 91
La Jolla Pharmaceutical Company is a biotechnology company leading
the development of therapeutics for antibody-mediated autoimmune
diseases afflicting several million people in the United States and Europe.
The Company is conducting a Phase III trial of LJP 394 in patients with
lupus kidney disease, a leading cause of sickness and death in these
patients. The Company is also conducting a Phase I/II trial of LJP 1082
for the treatment of antibody-mediated thrombosis, a condition in which
patients suffer from recurrent stroke, deep-vein thrombosis and other
thrombotic events. The Company's common stock is traded on The
Nasdaq Stock Market under the symbol LJPC. For more information
about the Company, visit our Web site: http://www.ljpc.com . Patients
interested in the Phase III lupus trial may call 1-800-30-LUPUS for
information.
Reuters
The Reuters’ Medical News database can be very useful in exploring news
archives relating to lupus nephritis. While some of the listed articles are free to view, others can be purchased for a nominal fee. To access this archive, go to
http://www.reutershealth.com/frame2/arch.html
and
search by “lupus nephritis” (or synonyms). The following was recently listed in this archive
for lupus nephritis:
·
Oral cyclophosphamide may have advantages in severe lupus nephritis
Source: Reuters Industry Breifing
Date: August 20, 2001
http://www.reuters.gov/archive/2001/08/20/business/links/20010820
clin017.html
·
Lupus nephritis may be mediated by molecular mimicry
Source: Reuters Medical News
Date: May 16, 2001
http://www.reuters.gov/archive/2001/05/16/professional/links/20010
516scie001.html
·
Anti-C1q antibodies are associated with lupus nephritis activity
Source: Reuters Medical News
Date: March 30, 2001
http://www.reuters.gov/archive/2001/03/30/professional/links/20010
330clin003.html
92 Lupus Nephritis
·
Increased risk of lupus nephritis linked to genetic factor in Caucasians
Source: Reuters Medical News
Date: March 13, 2001
http://www.reuters.gov/archive/2001/03/13/professional/links/20010
313clin007.html
·
Experimental agent may prevent flares of lupus nephritis
Source: Reuters Industry Breifing
Date: March 07, 2001
http://www.reuters.gov/archive/2001/03/07/business/links/20010307
drgd002.html
·
Mycophenolate mofetil plus prednisolone effective for lupus nephritis
Source: Reuters Medical News
Date: October 19, 2000
http://www.reuters.gov/archive/2000/10/19/professional/links/20001
019clin014.html
·
Chinese herbal preparation helps woman with lupus nephritis
Source: Reuters Medical News
Date: August 16, 1999
http://www.reuters.gov/archive/1999/08/16/professional/links/19990
816clin007.html
·
Tolerization with autoepitopes slows lupus nephritis in mice
Source: Reuters Medical News
Date: May 18, 1999
http://www.reuters.gov/archive/1999/05/18/professional/links/19990
518scie001.html
·
Compounds That Block DNA Antibodies May Prevent Lupus
Nephritis
Source: Reuters Medical News
Date: November 11, 1996
http://www.reuters.gov/archive/1996/11/11/professional/links/19961
111scie003.html
·
Genetic Risk Factor For Lupus Nephritis Identified
Source: Reuters Medical News
Date: March 06, 1996
http://www.reuters.gov/archive/1996/03/06/professional/links/19960
306clin002.html
Periodicals and News 93
The NIH
Within MEDLINEplus, the NIH has made an agreement with the New York
Times Syndicate, the AP News Service, and Reuters to deliver news that can
be browsed by the public. Search news releases at
http://www.nlm.nih.gov/medlineplus/alphanews_a.html.
MEDLINEplus
allows you to browse across an alphabetical index. Or you can search by date
at
http://www.nlm.nih.gov/medlineplus/newsbydate.html
. Often, news
items are indexed by MEDLINEplus within their search engine.
Business Wire
Business Wire is similar to PR Newswire. To access this archive, simply go to
http://www.businesswire.com
. You can scan the news by industry category or company name.
Internet Wire
Internet Wire is more focused on technology than the other wires. To access
this site, go to
http://www.internetwire.com
and use the “Search Archive”